Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 22.32
SNTA's Cash to Debt is ranked lower than
53% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. SNTA: 22.32 )
Ranked among companies with meaningful Cash to Debt only.
SNTA' s Cash to Debt Range Over the Past 10 Years
Min: 2.27  Med: 10.32 Max: N/A
Current: 22.32
F-Score: 3
Z-Score: -18.29
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -100.82
SNTA's ROE (%) is ranked lower than
82% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. SNTA: -100.82 )
Ranked among companies with meaningful ROE (%) only.
SNTA' s ROE (%) Range Over the Past 10 Years
Min: -1054.73  Med: -152.86 Max: -80.81
Current: -100.82
-1054.73
-80.81
ROA (%) -69.30
SNTA's ROA (%) is ranked lower than
80% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. SNTA: -69.30 )
Ranked among companies with meaningful ROA (%) only.
SNTA' s ROA (%) Range Over the Past 10 Years
Min: -98.31  Med: -85.32 Max: 108.22
Current: -69.3
-98.31
108.22
ROC (Joel Greenblatt) (%) -9186.90
SNTA's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. SNTA: -9186.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNTA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -6515.41  Med: -1413.59 Max: 1600.97
Current: -9186.9
-6515.41
1600.97
Revenue Growth (3Y)(%) -100.00
SNTA's Revenue Growth (3Y)(%) is ranked lower than
97% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. SNTA: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNTA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100.00 Max: 151.8
Current: -100
0
151.8
EBITDA Growth (3Y)(%) -3.20
SNTA's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. SNTA: -3.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNTA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.8  Med: 0.95 Max: 182.5
Current: -3.2
-29.8
182.5
EPS Growth (3Y)(%) -4.50
SNTA's EPS Growth (3Y)(%) is ranked higher than
51% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. SNTA: -4.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNTA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.3  Med: 3.60 Max: 187.6
Current: -4.5
-37.3
187.6
» SNTA's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

SNTA Guru Trades in Q2 2015

Murray Stahl 16,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q3 2015

SNTA Guru Trades in Q3 2015

Murray Stahl 18,000 sh (+12.50%)
» More
Q4 2015

SNTA Guru Trades in Q4 2015

Jim Simons 2,504,200 sh (New)
Murray Stahl 18,000 sh (unchged)
» More
Q1 2016

SNTA Guru Trades in Q1 2016

Murray Stahl 18,000 sh (unchged)
Jim Simons 2,332,995 sh (-6.84%)
» More
» Details

Insider Trades

Latest Guru Trades with SNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:EBIO, NAS:BCLI, NAS:CBAY, OTCPK:ONCYF, OTCPK:GRSO, OTCPK:BIOAF, OTCPK:PMCB, NAS:PRAN, NAS:CNAT, NAS:OCRX, OTCPK:ORGS, OTCPK:EMIS, NAS:VICL, OTCPK:VNAPF, NAS:BLRX, OTCPK:OGRMF, NAS:SNSS, NAS:AEGR, OTCPK:IMMVF, NAS:IPCI » details
Traded in other countries:YDO.Germany,
Synta Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients.

Synta Pharmaceuticals Inc was incorporated in Delware in March 2000 and commenced operations in July 2001. It is a biopharmaceutical company engaged in research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Its drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer (NSCLC) and in development program, including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia. In addition, it is developing several candidates from its proprietary Hsp90 inhibitor Drug Conjugate program (HDC Program), which leverages the preferential accumulation of Hsp90 inhibitors in tumors to selectively deliver an array of anti-cancer payloads. It also has an additional clinical-stage oncology candidate: elesclomol, a mitochondrial metabolism inhibitor. Its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. Its patent portfolio has a total of 867 patents and patent applications.

Ratios

vs
industry
vs
history
P/B 0.81
SNTA's P/B is ranked higher than
90% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. SNTA: 0.81 )
Ranked among companies with meaningful P/B only.
SNTA' s P/B Range Over the Past 10 Years
Min: 0.17  Med: 5.35 Max: 28.61
Current: 0.81
0.17
28.61
EV-to-EBIT 0.24
SNTA's EV-to-EBIT is ranked higher than
98% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 22.57 vs. SNTA: 0.24 )
Ranked among companies with meaningful EV-to-EBIT only.
SNTA' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.1  Med: -2.50 Max: 2.2
Current: 0.24
-10.1
2.2
EV-to-EBITDA 0.24
SNTA's EV-to-EBITDA is ranked higher than
98% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 19.06 vs. SNTA: 0.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNTA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.2  Med: -2.50 Max: 2.1
Current: 0.24
-10.2
2.1
Current Ratio 6.09
SNTA's Current Ratio is ranked higher than
60% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SNTA: 6.09 )
Ranked among companies with meaningful Current Ratio only.
SNTA' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 3.58 Max: 7.01
Current: 6.09
0.43
7.01
Quick Ratio 6.09
SNTA's Quick Ratio is ranked higher than
61% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. SNTA: 6.09 )
Ranked among companies with meaningful Quick Ratio only.
SNTA' s Quick Ratio Range Over the Past 10 Years
Min: 0.43  Med: 3.58 Max: 7.01
Current: 6.09
0.43
7.01

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.84
SNTA's Price/Net Cash is ranked higher than
95% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. SNTA: 0.84 )
Ranked among companies with meaningful Price/Net Cash only.
SNTA' s Price/Net Cash Range Over the Past 10 Years
Min: 0.77  Med: 7.48 Max: 80.9
Current: 0.84
0.77
80.9
Price/Net Current Asset Value 0.81
SNTA's Price/Net Current Asset Value is ranked higher than
95% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. SNTA: 0.81 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SNTA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.75  Med: 7.13 Max: 50.56
Current: 0.81
0.75
50.56
Price/Tangible Book 0.81
SNTA's Price/Tangible Book is ranked higher than
93% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. SNTA: 0.81 )
Ranked among companies with meaningful Price/Tangible Book only.
SNTA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.75  Med: 6.68 Max: 29.91
Current: 0.81
0.75
29.91
Earnings Yield (Greenblatt) (%) 397.53
SNTA's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. SNTA: 397.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNTA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 45.3  Med: 91.25 Max: 1539.2
Current: 397.53
45.3
1539.2

More Statistics

EPS (TTM) $ -0.41
Beta0.77
Short Percentage of Float4.74%
52-Week Range $0.15 - 2.37
Shares Outstanding (Mil)137.81

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.72 -0.97 -0.75
EPS w/o NRI ($) -0.72 -0.97 -0.75
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for SNTA

Headlines

Articles On GuruFocus.com
Insiders Sell Twitter and Cannabis Science, Buy DSW and WhiteHorse Dec 04 2015 
Stocks Both Gurus and Company Insiders Are Buying Jun 18 2015 
Insider Buys: FULL, FMI and SNTA Apr 10 2015 
Weekly 3-Year Low Highlights: NSR, ELRC, PLPC, SNTA Feb 16 2015 
5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp. Feb 08 2015 
5-year lows: Synta Pharmaceuticals Inc, Rex Energy Corp, Petroquest Energy Inc, and Liquidity Servic Jan 11 2015 
5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic Communications Inc, and Aeropostale I Dec 28 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 

More From Other Websites
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 08 2016
Synta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal... Jun 08 2016
Synta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal... Jun 08 2016
SYNTA PHARMACEUTICALS CORP Financials Jun 08 2016
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events Jun 03 2016
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 02 2016
Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June Jun 02 2016
Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June Jun 02 2016
VKTX: Phase 2 Study of VK5211 for Hip Fracture Ongoing; Phase 2 Study of VK2809 for... May 16 2016
Synta (SNTA) Lowers Q1 Loss Y/Y, Focus on Madrigal Merger May 11 2016
Synta reports 1Q loss May 10 2016
Synta reports 1Q loss May 10 2016
SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report May 10 2016
What's in the Cards for Synta (SNTA) This Earnings Season? May 05 2016
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 03 2016
SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Termination of a Material Definitive Agreement,... Apr 22 2016
The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen Apr 21 2016
Biotech Stock Roundup: Medivation Buyout Rumors Resurface, Synta Up on Merger Deal Apr 20 2016
Synta Pharmaceuticals Corp (SNTA): Billionaire Bruce Kovner Buys More Shares Apr 17 2016
Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals Apr 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)